Orion Pharma Limited

DSE:ORIONPHARM Stock Report

Market Cap: ৳8.7b

Orion Pharma Valuation

Is ORIONPHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ORIONPHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ORIONPHARM (BDT37.2) is trading above our estimate of fair value (BDT11.08)

Significantly Below Fair Value: ORIONPHARM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ORIONPHARM?

Key metric: As ORIONPHARM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ORIONPHARM. This is calculated by dividing ORIONPHARM's market cap by their current earnings.
What is ORIONPHARM's PE Ratio?
PE Ratio44.2x
Earnings৳196.78m
Market Cap৳8.70b

Price to Earnings Ratio vs Peers

How does ORIONPHARM's PE Ratio compare to its peers?

The above table shows the PE ratio for ORIONPHARM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.7x
IBNSINA IBN SINA Pharmaceutical Industry
15.3x25.5%৳9.0b
ORIONINFU Orion Infusion
143.9xn/a৳6.1b
ACMELAB ACME Laboratories
6.3xn/a৳15.3b
NAVANAPHAR Navana Pharmaceuticals
13.3xn/a৳5.4b
ORIONPHARM Orion Pharma
44.2xn/a৳8.7b

Price-To-Earnings vs Peers: ORIONPHARM is good value based on its Price-To-Earnings Ratio (44.2x) compared to the peer average (44.7x).

Price to Earnings Ratio vs Industry

How does ORIONPHARM's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ORIONPHARM 44.2xIndustry Avg. 24.2xNo. of Companies74PE020406080100+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ORIONPHARM is expensive based on its Price-To-Earnings Ratio (44.2x) compared to the Asian Pharmaceuticals industry average (24x).

Price to Earnings Ratio vs Fair Ratio

What is ORIONPHARM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ORIONPHARM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ORIONPHARM's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies